NMT Medical Appoints Chief Operating Officer Richard E. Davis to Board of Directors

BOSTON--(Business Wire)--
NMT Medical, Inc. (NASDAQ: NMTI), an advanced medical technology company that
designs, develops, manufactures and markets proprietary implant technologies
that allow interventional cardiologists to treat structural heart disease
through minimally invasive, catheter-based procedures, today announced that its
Board of Directors has appointed the Company`s Chief Operating Officer, Richard
E. Davis, 51, to serve on the Board.

"Rick`s long tenure at NMT and his breadth of financial and operational
experience will be a strong asset to our Board," said James J. Mahoney, Jr.,
Chairman of NMT`s Board of Directors. "His deep knowledge of the Company`s
business will help lead NMT as we pursue the exciting opportunities in the
treatment of structural heart disease. We are pleased to welcome Rick to our
Board and look forward to his continued valuable insights."

Mr. Davis has served as NMT`s Chief Financial Officer and Corporate Secretary
since February 2001 and was promoted to Chief Operating Officer in February
2009. From August 2000 to February 2001, Mr. Davis served as the Interim Chief
Financial Officer through his employment with the consulting firm of Argus
Management Corporation. From July 1998 to July 2000, Mr. Davis was Vice
President and Chief Financial Officer of Q-Peak, Inc., a marketer and
manufacturer of solid-state laser systems. Prior to July 1998, Mr. Davis served
in various senior financial management positions at TJX Companies, Inc. for 10
years.

About NMT Medical, Inc.

NMT Medical is an advanced medical technology company that designs, develops,
manufactures and markets proprietary implant technologies that allow
interventional cardiologists to treat structural heart disease through minimally
invasive, catheter-based procedures. NMT Medical is currently investigating the
potential connection between a common heart defect that allows a right to left
shunt or flow of blood through a defect like a patent foramen ovale (PFO) and
brain attacks such as embolic stroke, transient ischemic attacks (TIAs) and
migraine headaches. A common right to left shunt can allow venous blood,
unfiltered and unmanaged by the lungs, to enter the arterial circulation of the
brain, possibly triggering a cerebral event or brain attack. More than 30,000
PFOs have been treated globally with NMT's minimally invasive, catheter-based
implant technology.

Stroke is the third leading cause of death in the United States and the leading
cause of disability in adults. Each year, 750,000 Americans suffer a new or
recurrent stroke and an additional 500,000 Americans experience a TIA.

For more information about NMT Medical, please visit www.nmtmedical.com.

NMT Medical, Inc.
Frank Martin, 617-737-0930
President, Chief Executive Officer
fjm@nmtmedical.com

Copyright Business Wire 2009